Buradasınız

Anasayfa » Content

Lisinopril, Sildenafil ve Birlikte Kullanımlarının Karın İçi Yapışıklık Oluşmasını Önleyici Etkileri

The Preventing Effects of Lisinopril, Sildenafil and Combined Usage of Them on the Formation of Intra-Abdominal Adhesion

Journal Name:

  • Fırat Tıp Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: In this study, it was aimed to compare the effectiveness of lisinopril and sildenafil on the prevention of intraabdominal adhesions and to investigate whether there was a synergistic effect if they were combined. Materials and Methods: Fourty rats divided into four groups and mesothelial damage created. No medication was given to rats in group 1, lisinopril (6.5 mg/kg/d) in group 2, sildenafil (0.8 mg/kg/d) in group 3, and lisinopril combined with sildenafil in group 4 were given to rats by gavage for 7 days. Then, abdominal cavities were re-opened and adhesion scores were determined. Results: The mean intra-abdominal adhesion scores of groups were 2.3±0.5, 0.9±0.7, 0.6±0.8, and 0.7±0.9, respectively. The mean adhesion scores of all treatment groups were significantly lower than control group (p<0.001). Whereas, there were no statistically differences between treatment groups (group 2 vs group 4 p>0.05,and group 3 vs group 4 p>0.5). Conclusion: : Lisinopril and sildenafil alone is effective in preventing the formation of intra-abdominal adhesions. Their combination does not increase their potencies.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bu çalışmada lisinopril ve sildenafilin karın içi yapışıklıkları önlemedeki etkinliklerinin karşılaştırılması ve birlikte uygulanmaları halinde sinerjik etki gösterip göstermeyeceklerinin incelenmesi amaçlanmıştır. Gereç ve Yöntem: Kırk adet rat 4 gruba ayrılıp mezotel hasarı oluşturuldu. Birinci gruptaki ratlara her hangi bir ilaç verilmez iken 2. gruptakilere lisinopril (6.5 mg/kg/gün), 3. gruptakilere sildenafil (0.8 mg/kg/gün) ve 4. gruptakilere hem lisinopril hem de sildenafil gavaj yoluyla 7 gün verildi. Sonra karın boşluğu tekrar açılıp yapışıklık skorları belirlendi. Bulgular: Grupların ortalama karın içi yapışıklık skorları sırasıyla 2.3±0.5, 0.9±0.7, 0.6±0.8 ve 0.7±0.9 idi. Tüm tedavi gruplarının yapışıklık skorları kontrol grubununkinden belirgin olarak daha düşüktü (p<0.001). Halbuki tedavi grupları arasında istatistiksel olarak anlamlı farklılık yoktu (grup 2 vs grup 4 p>0.05, grup 3 vs grup 4 p>0.5). Sonuç: Lisinopril ve sildenafil tek başlarına karın içi yapışıklık gelişmesini önlemede etkilidir. Birlikte kullanımları onların güçlerini artırmaz.
FULL TEXT (PDF): 
PDF icon arastirmax-lisinopril-sildenafil-birlikte-kullanimlarinin-karin-ici-yapisiklik-olusmasini-onleyici-etkileri.pdf
  • 4
167-169
  • Turkish

REFERENCES

References: 

1.
Hellebreker
s B, Trimbos-Kemper T, Trimbos J, Emeis J, Kooistra T. Use of fibrinolytic agents in the prevention of post-operative adhesion formation. Fertil Steril 2000; 74: 203¬212.
2. Nair S, Bhat I, Aurora A. Role of proteolytic enzyme in the prevention of post-operative intraperitoneal adhesions. Arch
Surg 1974; 108: 849-853.
3. Kıkırdak T, Uysal E, Korun N. Karın içi yapışıklıkların ön¬lenmesinde metilprednizolonun farklı dozlarının etkinliğinin incelenmesi. Ulus Travma Acil Cerrahi Derg 2008; 14: 188¬191.
4. Lauder CIW, Garcea G, Strickland A, Maddern GJ. Abdominal adhesion prevention: Stil a sticky subject? Dig Surg 2010; 27: 347- 358.
5. Bulbuller N, Ilhan YS, Kirkil C, Cetiner M, Gogebakan O,
Ilhan N. Can angiotensin converting enzyme inhibitors prevent
postoperativ adhesions? J Surg Res 2005; 125: 94-97.
6. Batukan C, Ozgun MT, Basbug M, Muderris II. Sidenafil reduces postoperative adhesion formation in a rat uterine horn
model. Eur J Obstet Gynecol Reprod Biol 2007; 135: 183-187.
7. Mollnau H, Wendt M, Szocs K et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90: 58-65.
8. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA.
Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 2002; 277: 3310-3317.
9. Krause TJ, Zazanis GA, McKinnon RD. Prevention of postoperative adhesions with the chitin derivate N-O-carboxymethylchitosan. Wound Repair Regen 1996; 4: 53-57.
10. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991; 83: 13¬25.
11. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured
murine mesengial cells. Am J Pathol 1992; 140: 95-107.
12. Brilla CG, Maisch B, Weber KT. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertansive heart disease. In vivo and in vitro studies on collagen matrix regulation. Coin Invest 1993; 71: 35-41.
13. Weber KT, Sun Y, Tyagi SC, Clentjens JP. Collagen network
of the myocardium: function, structural remodeling and
regulatory mechanisms. J Mol Cell Cardiol 1994; 26: 279-292.
14. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type I receptor. Am J Respir Crit Care Med 2000; 161: 1999-2004.
15. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
16. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-p expression in rat glomerular mesengial cells. J Clin Invest 1994; 93: 2431-2437.
17. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
18. Roberts AR. Transforming growth factor-b: Activity and efficacy in animal models of wound healing. Wound Repair Regeneration 1995; 3: 408-418.
19. Williams RS, Rossi AM, Chegini N, Schultz G. Effect of
transforming growth factor p on postoperative adhesion formation and intact peritoneum. J Surg Res 1992; 52: 65-70.
20. Chegini N. The role of growth factors in peritoneal healing: Transforming growth factor beta (TGF-beta). Eur J Surg 1997;
577: 17-23.
21. Lucas PA, Warejcka DJ, Young HE, Lee BY. Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor-p1. J Surg Res 1996; 65: 135-138.
22. Zhang H, Pakeerappa P, Lee HJ, Fisher SA. Induction of PDE5 and de-sensitization to endogenous NO signaling in a systemic resistance artery under altered blood flow. J Mol Cell
Cardiol 2009; 47: 57-65.
23. Colle I, De Vriese, Van Vlierberghe H, Lamerie NH, De Vos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrotic patients. Liver Int 2004; 24: 63-68.
24. Sirotkin AV, Makarevich AV, Pivko J, Kotwica J, Genieser H, Bulla J. Effect of cGMP analogues and protein kinase G blocker on secretory activity, apoptosis and the cAMP/protein kinase A system in porcine ovarian granulosa cells in vitro. J Steroid Biochem Mol Biol 2000; 74: 1-9.
25. Redondo J, Bishop JE,Wilkins MR. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol 1998; 124: 1455-1462.
26. Ayten R, Cetinkaya Z, Girgin M,Ozercan I, Ustundag B, Aygen E. The effects of intraperitoneal sildenafil administration on healing of left colonic anastomoses and intra-abdominal adhesion formation in the presence of intra-abdominal infection. Dis Colon Rectum 2008; 51: 1837-1841.
27. Joannides R, Bizet-Nafeh C, Costentin A et al. Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure. Hypertension 2001; 38: 1446-1450.
28. Katz SD, Balidemaj K, Homma S,Wu H, Wang J, Maybaum
S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic
heart failure. J Am Coll Cardiol 2000; 36: 845-851.
29. Hryniewicz K, Dimayuga C, Hudaihed A, et al. Inhibition of angiotesin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci 2005;
108: 331-338.

Thank you for copying data from http://www.arastirmax.com